Product name: S4
Molecular Formula: C19H18F3N3O6
Description: S4 is under development as one of the most powerful SARMS to date with key attributes and elements being notable changes in muscle mass and performance.
||Premium Ceramic Dropper
||1 x Bottle S-4 (30ml)
||Premium Research Chemicals
Elite Scientific Analysis:
S-4 (Andarine) is under development as a treatment for muscle wasting, osteoporosis and benign prostatic hypertrophy with key attributes and elements being notable changes in muscle mass and performance.
Initially conceived using the non-steroidal antiandrogen bicalutamide as a lead compound, S-4 is an orally active partial agonist for androgen receptors. It is less potent in anabolic effects than other selective androgen receptor modulators but is one of the most androgenic and has almost one third the affinity of testosterone when binding to the androgen receptor.
In an animal model of benign prostatic hypertrophy andarine was shown to reduce prostate weight but has no anti-androgenic side effects. This suggests that it is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland, but its partial agonist effects at androgen receptors prevent the side effects associated with the anti-androgenic drugs.
S-4 also results in weight loss by binding to the androgen receptors allowing fat to be oxidised more readily and it displays nutrient partitioning effects causing more calories to be used to build and repair muscle tissue.
The compound has mild anti-oestrogen qualities, and will lower oestrogen in a subject over a four week period.
S-4 studies have been halted due to some effects of the metabolite M1 that binds to the ocular receptor and has temporary effects on vision when the compound is used for extended periods of time.
Chen J., Kim J., Dalton J. T., Discovery and therapeutic promise of selective androgen receptor modulators, Molecular Interventions, 2005, 5 (3), 173–88.
Gao W., Kearbey J. D., Nair V. A., Chung K., Parlow A. F., Miller D. D., Dalton J. T., Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia, Endocrinology, 2004, 145 (12), 5420–8.